IV Contrast-Enhanced Cone Beam Computed Tomography (CBCT) in Radiotherapy

NCT04199754 · Status: TERMINATED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2024-05-31

No results posted yet for this study

Summary

The purpose of this study is to find out if giving intravenous (IV) contrast (a liquid that helps with the visibility of organs and blood vessels that is given through the vein with the use of a hollow needle) during a Cone Beam Computed Tomography (CBCT- a type of computerized X-ray) can help people who have image guided radiation therapy (IGRT) for the treatment of abdominal and pelvic tumors.

Conditions

  • Pelvic Cancer
  • Abdominal Cancer

Interventions

DRUG

Omnipaque 300mg/mL Solution for Injection

Prior to the contrast enhanced Cone Beam CT, 100mL of Omnipaque will be administered by IV at a rate of 2mL per second, followed by administration of 50mL of 0.9% saline.

RADIATION

Cone Beam CT

60 seconds after contrast administration, a Cone Beam CT will be performed.

RADIATION

Radiation Therapy

Standard of Care Radiation Therapy will be administered, dosage depends on the type of tumor being treated.

DRUG

0.9% Saline

50 ML of 0.9% Saline will be administered immediately after Omnipaque administration

Sponsors & Collaborators

Principal Investigators

  • David Horowitz, MD · Assistant Professor of Radiation Oncology at Columbia University Medical Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-01
Primary Completion
2021-05-28
Completion
2021-05-28
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04199754 on ClinicalTrials.gov